BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer

ABSTRACT Gastric cancer is among the most common gastrointestinal malignancies. Recent studies have suggested that bone morphogenetic protein-2 (BMP2) is related to the development and progression of various cancers. Meanwhile, evidence suggests that BMP2 might lead to epigenetic changes in gastric cancer. Thus, we investigated whether BMP2 plays a role in the development of gastric cancer via epigenetic regulation. Cell viability, colony formation, and cell cycle assays were performed to assess the effect of recombinant human BMP2 (rhBMP2) in gastric cancer cells. LDN-193189 and Noggins were used as antagonists of the canonical BMP-SMAD signaling pathway. The protein levels were determined using a western blot analysis. Lentiviral vectors with EZH2 shRNA or EZH2 overexpression were used to mediate the role of EZH2 and the relationship between BMP2 and EZH2 in gastric cancer. We found that rhBMP2 inhibits cell proliferation by arresting the cell cycle in HGC-27 and SNU-216 gastric cancer cells. Neither LDN-193189 nor Noggins, antagonists of the canonical BMP-SMAD signaling pathway, can reverse the effect of rhBMP2 on gastric cancer. Molecularly, rhBMP2 downregulates the expression of EZH2 and H3K27me3, leading to increases in P16 and P21 and decreases in CDK2, CDK4, and CDK6. Altogether, in this study, we demonstrate that BMP2 serves as a tumor suppressor in gastric cancer cells by downregulating EZH2 and H3K27me3 through the non-SMAD BMP pathway, suggesting that BMP2 might be a new therapeutic target for gastric cancer treatment. Abbreviations: BMP: bone morphogenetic protein; TGF-β: transforming growth factor-beta; EZH2: enhancer of zeste homolog 2; H3K27me3: trimethylation histone H3 lysine 27; HRECs: human retinal endothelial cells; PcG: polycomb group; PRC: polycomb repressive complexes.

[1]  P. Yu,et al.  Bone Morphogenetic Protein-2 Induces Non-Canonical Inflammatory and Oxidative Pathways in Human Retinal Endothelial Cells , 2021, Frontiers in Immunology.

[2]  F. Jirik,et al.  Is Use of BMP-2 Associated with Tumor Growth and Osteoblastic Differentiation in Murine Models of Osteosarcoma? , 2020, Clinical orthopaedics and related research.

[3]  A. V. van Wijnen,et al.  Combination of BMP2 and EZH2 inhibition to stimulate osteogenesis in a 3D bone reconstruction model. , 2020, Tissue engineering. Part A.

[4]  Xiaobin Wu,et al.  Exosome-Delivered LncHEIH Promotes Gastric Cancer Progression by Upregulating EZH2 and Stimulating Methylation of the GSDME Promoter , 2020, Frontiers in Cell and Developmental Biology.

[5]  Weijian Guo,et al.  EZH2: a novel target for cancer treatment , 2020, Journal of Hematology & Oncology.

[6]  A. V. van Wijnen,et al.  Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2 , 2020, The Journal of Biological Chemistry.

[7]  H. El‐Serag,et al.  Burden of Gastric Cancer. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  Yongchun Zhang,et al.  BMP Signaling in Development, Stem Cells, and Diseases of the Gastrointestinal Tract. , 2020, Annual review of physiology.

[9]  Siyu Yang,et al.  The role and prospect of JMJD3 in stem cells and cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  S. Luo,et al.  Effects of microRNA-378 on epithelial-mesenchymal transition, migration, invasion and prognosis in gastric carcinoma by targeting BMP2. , 2019, European review for medical and pharmacological sciences.

[11]  E. Alsberg,et al.  Combinatorial morphogenetic and mechanical cues to mimic bone development for defect repair , 2019, Science Advances.

[12]  Jianbao Zheng,et al.  Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway , 2019, International journal of oncology.

[13]  Prashanth Rawla,et al.  Epidemiology of gastric cancer: global trends, risk factors and prevention , 2018, Przeglad gastroenterologiczny.

[14]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[15]  Ling Yan,et al.  Evaluation of the effects of the combination of BMP-2-modified BMSCs and PRP on cartilage defects , 2018, Experimental and therapeutic medicine.

[16]  Qian Li,et al.  Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential , 2018, Biomarker Research.

[17]  Midie Xu,et al.  The polycomb group protein EZH2 induces epithelial–mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter , 2018, Journal of Hematology & Oncology.

[18]  J. Sen,et al.  Perturbation of canonical and non-canonical BMP signaling affects migration, polarity and dendritogenesis of mouse cortical neurons , 2018, Development.

[19]  Jeffrey C. Wang,et al.  Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy. , 2017, Cytokine & growth factor reviews.

[20]  Byung-Hyun Park,et al.  Recombinant human bone morphogenetic protein-2 inhibits gastric cancer cell proliferation by inactivating Wnt signaling pathway via c-Myc with aurora kinases , 2016, Oncotarget.

[21]  Baolin Wang,et al.  BMP regulates regional gene expression in the dorsal otocyst through canonical and non-canonical intracellular pathways , 2016, Development.

[22]  Samuel K. Cho,et al.  Association Between BMP-2 and Carcinogenicity , 2015, Spine.

[23]  Yoon Young Choi,et al.  Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine , 2015, Yonsei medical journal.

[24]  Jianping Zhang,et al.  C23 protein meditates bone morphogenetic protein-2-mediated EMT via up-regulation of Erk1/2 and Akt in gastric cancer , 2015, Medical Oncology.

[25]  Dawei Sun,et al.  RETRACTED ARTICLE: Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer , 2015, Tumor Biology.

[26]  E. Hurwitz,et al.  Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. , 2013, The Journal of bone and joint surgery. American volume.

[27]  Zhirong Wang,et al.  Effect of Bone Morphogenetic Protein-2 on Proliferation and Apoptosis of Gastric Cancer Cells , 2012, International journal of medical sciences.

[28]  K. Miyazono,et al.  Bone morphogenetic protein-2 and -4 play tumor suppressive roles in human diffuse-type gastric carcinoma. , 2011, The American journal of pathology.

[29]  H. Aburatani,et al.  Activation of Bmp2-Smad1 Signal and Its Regulation by Coordinated Alteration of H3K27 Trimethylation in Ras-Induced Senescence , 2011, PLoS genetics.

[30]  Jung lim Kim,et al.  Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression. , 2011, Experimental cell research.

[31]  Guy Sauvageau,et al.  Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. , 2010, Cell stem cell.

[32]  A. Hoffmann,et al.  Enhancement of endoprosthesis anchoring using BMP-2. , 2010, Technology and health care : official journal of the European Society for Engineering and Medicine.

[33]  K. Helin,et al.  Polycomb group protein-mediated repression of transcription. , 2010, Trends in biochemical sciences.

[34]  S. Oh,et al.  BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. , 2010, Experimental cell research.

[35]  S. Oh,et al.  The Bone Morphogenesis Protein-2 (BMP-2) is associated with progression to metastatic disease in gastric cancer. , 2008, Cancer research and treatment : official journal of Korean Cancer Association.

[36]  S. Baylin,et al.  Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas , 2006, Oncogene.

[37]  Y. Yuasa,et al.  BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. , 2004, Biochemical and biophysical research communications.

[38]  J. Keller,et al.  Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. , 2003, Gastroenterology.

[39]  Jun Ho Jeon,et al.  Aberrant signaling of TGF-beta1 by the mutant Smad4 in gastric cancer cells. , 2003, Cancer letters.

[40]  H. Iba,et al.  Application of efficient and specific gene transfer systems and organ culture techniques for the elucidation of mechanisms of epithelial– mesenchymal interaction in the developing gut , 2000, Development, growth & differentiation.

[41]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[42]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988, Science.

[43]  M. Urist,et al.  Solubilized and insolubilized bone morphogenetic protein. , 1979, Proceedings of the National Academy of Sciences of the United States of America.